Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hyperglycemia and hypoglycemia currently are considered risk factors for cardiovascular disease in type 1diabetes. Both acute hyperglycemia and hypoglycemia induce endothelial dysfunction and inflammation, raising the oxidative stress. Glucagon-like peptide 1 (GLP-1) has antioxidant properties, and evidence suggests that it protects endothelial function. RESEARCH DESIGN AND METHODS: The effect of both acute hyperglycemia and acute hypoglycemia in type 1 diabetes, with or without the simultaneous infusion of GLP-1, on oxidative stress (plasma nitrotyrosine and plasma 8-iso prostaglandin F2alpha), inflammation (soluble intercellular adhesion molecule-1 and interleukin-6), and endothelial dysfunction has been evaluated. RESULTS: Both hyperglycemia and hypoglycemia acutely induced oxidative stress, inflammation, and endothelial dysfunction. GLP-1 significantly counterbalanced these effects. CONCLUSIONS: These results suggest a protective effect of GLP-1 during both hypoglycemia and hyperglycemia in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of T2DM, GLP-1RAs have produced a range of beneficial pancreatic impacts, leading to significant enhancements in glycated hemoglobin (HbA1c), fasting and postprandial plasma glucose levels, and pancreatic beta-cell performance indicators.72–74”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In people with T1D, GLP-1 infusion counteracted hypo- and hyperglycemia-induced increases in the inflammation markers IL-6 and soluble intercellular adhesion molecule-1 (sICAM-1) (45).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
The Value of Cardiovascular Autonomic Function Tests: 10 Years Experience in Diabetes
Ewing, D. J., Martyn, C. N., Young, R. J., & Clarke, B. F. (1985) · Diabetes Care · doi:10.2337/diacare.8.5.491 · Cited by 1,434
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress
Mercuri, F., Tonutti, L., Taboga, C., Ceriello, A., Assaloni, R., Motz, E., & Quagliaro, L. (2001) · Diabetologia · doi:10.1007/s001250100529 · Cited by 419
Self-citationVascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 2×
“Recent evidence suggests that hypoglycemia also may play an important role in favoring diabetic vascular complications (1).”
BackgroundAmiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267
Gogitidze Joy, N., Hedrington, M. S., Briscoe, V. J., Tate, D. B., Ertl, A. C., & Davis, S. N. (2010) · Diabetes Care · doi:10.2337/dc09-0354 · Cited by 239
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects
Razavi Nematollahi, L., Kitabchi, A. E., Stentz, F. B., Wan, J. Y., Larijani, B. A., Tehrani, M. M., Gozashti, M. H., Omidfar, K., & Taheri, E. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.018 · Cited by 210
Effects of Acute Insulin-Induced Hypoglycemia on Indices of Inflammation
Wright, R. J., Newby, D. E., Stirling, D., Ludlam, C. A., Macdonald, I. A., & Frier, B. M. (2010) · Diabetes Care · doi:10.2337/dc10-0013 · Cited by 208 · cited 2×
“Evidence suggests that both hyperglycemia and hypoglycemia can induce endothelial dysfunction and inflammation, producing oxidative stress (3,4,7).”
BackgroundSingh, P. K., Jain, A., & Kaur, G. (2004) · Molecular and Cellular Biochemistry · doi:10.1023/b:mcbi.0000026067.08356.13 · Cited by 163
Ceriello, A., Novials, A., Ortega, E., La Sala, L., Pujadas, G., Testa, R., Bonfigli, A. R., Esposito, K., & Giugliano, D. (2012) · Diabetes · doi:10.2337/db12-0224 · Cited by 155
Self-citationMonnier, L., Colette, C., Mas, E., Michel, F., Cristol, J., Boegner, C., & Owens, D. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1574-6 · Cited by 144
Wang, J., Alexanian, A., Ying, R., Kizhakekuttu, T. J., Dharmashankar, K., Vasquez-Vivar, J., Gutterman, D. D., & Widlansky, M. E. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.227389 · Cited by 136
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134
Self-citationIncretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119
Costacou, T., Ferrell, R. E., & Orchard, T. J. (2008) · Diabetes · doi:10.2337/db08-0095 · Cited by 115
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 73
Ceriello, A. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368193.24732.66 · Cited by 51
Self-citationWhen Are Type 1 Diabetic Patients at Risk for Cardiovascular Disease?
Orchard, T. J., & Costacou, T. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0089-3 · Cited by 44
Nandish, S., Wyatt, J., Bailon, O., Smith, M., OLIVEROS, R. A., & CHILTON, R. J. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.015 · Cited by 32
Ceriello, A., Esposito, K., Ihnat, M. A., Thorpe, J. E., & Giugliano, D. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02928.x · Cited by 30
Self-citationCostacou, T., Zgibor, J. C., Evans, R. W., Tyurina, Y. Y., Kagan, V. E., & Orchard, T. J. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.10.007 · Cited by 23
Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus
Issa, C. M., & Azar, S. T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0291-6 · Cited by 15
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Burgos-Morón, E., Abad-Jiménez, Z., Martínez de Marañón, A., Iannantuoni, F., Escribano-López, I., López-Domènech, S., Salom, C., Jover, A., Mora, V., Roldan, I., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091385 · Cited by 581
Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Metadata
- Authors
- Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S.
- Affiliations
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Diabetes and Endocrinology, Insititut d'Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Hospital Clínic Barcelona, Barcelona, Spain
- University of Campania "Luigi Vanvitelli" (IT)
- MultiMedica (IT)
- Corresponding author
- Ceriello, Antonio
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-11
- Volume
- 36
- Issue
- 8
- Pages
- 2346-2350
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3714509
- OpenAlex
- W2148254941
- Cited by
- 204
- References
- 28
- Citations by year
- 2026: 16 · 2025: 11 · 2024: 16 · 2023: 19 · 2022: 16 · 2021: 23 · 2020: 12 · 2019: 17 · 2018: 10 · 2017: 9 · 2016: 22 · 2015: 19 · 2014: 10 · 2013: 4
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- glucagon-like peptide-1, type 1 diabetes, hyperglycemia, hypoglycemia, endothelial dysfunction, oxidative stress, inflammation, nitrotyrosine, 8-isoprostane, interleukin-6, soluble intercellular adhesion molecule-1, cardiovascular risk
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Endothelium, Vascular, Female, Humans, Hyperglycemia, Hypoglycemia, Inflammation, Male, Interleukin-6, Oxidative Stress, Intercellular Adhesion Molecule-1, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.